Close-up of a blue microscopic structure resembling a virus with detailed surface textures.

The Ultimate Non-invasive Test for Preeclampsia

The Ultimate Non-invasive Test for Preeclampsia

The first urine test to predict preeclampsia months in advance.

Featured News - December 4, 2025

SavranTech to Present Results of Preeclampsia Study at SRI 2026 Conference

[Read More →]

SavranTech develops diagnostics for critical conditions in women’s health

SavranTech develops diagnostics for critical conditions in women’s health

SavranTech develops diagnostics for critical conditions in women’s health

Our mission is to revolutionize women’s health diagnostics through non-invasive tests that provide reliable screening at the earliest actionable time, powered by our patented ultra-rare cell detection platform.

The Problem & Detection Gap

Preeclampsia is a serious, potentially life-threatening pregnancy complication characterized by high blood pressure and organ dysfunction, typically emerging after 20 weeks of gestation.


Impact on mothers:

• Affects 1 in 12 pregnancies worldwide.

• If undetected, can rapidly escalate to seizures, stroke, organ failure, or even maternal death.


Significant threat to babies:

• Leading cause of preterm birth, responsible for 15% of premature deliveries globally.

• Higher risks of growth restriction, respiratory complications, developmental delays, and neonatal death.

Global impact: Preeclampsia affects over 10 million women each year and is a leading cause of maternal and fetal mortality worldwide, contributing to more than 500,000 infant deaths annually.

Global impact: Preeclampsia affects over 10 million women each year and is a leading cause of maternal and fetal mortality worldwide, contributing to more than 500,000 infant deaths annually.

Global impact: Preeclampsia affects over 10 million women each year and is a leading cause of maternal and fetal mortality worldwide, contributing to more than 500,000 infant deaths annually.

Late detection: Current screening methods are indirect, nonspecific, and often too late for effective intervention.

Late detection: Current screening methods are indirect, nonspecific, and often too late for effective intervention.

Late detection: Current screening methods are indirect, nonspecific, and often too late for effective intervention.

Unmet need: There is urgent demand for early, non-invasive, and clinically actionable detection.

Unmet need: There is urgent demand for early, non-invasive, and clinically actionable detection.

Unmet need: There is urgent demand for early, non-invasive, and clinically actionable detection.

Our Solution

“The optimal window to begin aspirin prophylaxis for preeclampsia prevention is between 12 and 16 weeks of gestation.”

— American College of Obstetricians and Gynecologists (ACOG)

Simple urine test: Detect upstream biomarkers directly related to preeclampsia

Simple urine test: Detect upstream biomarkers directly related to preeclampsia

Simple urine test: Detect upstream biomarkers directly related to preeclampsia

1st trimester detection: As early as 10 weeks GA

1st trimester detection: As early as 10 weeks GA

1st trimester detection: As early as 10 weeks GA

Full pregnancy coverage: Test anytime from 10 weeks to delivery

Full pregnancy coverage: Test anytime from 10 weeks to delivery

Full pregnancy coverage: Test anytime from 10 weeks to delivery

Predicts all forms of preeclampsia

Predicts all forms of preeclampsia

Predicts all forms of preeclampsia

Straightforward report, no complexity

Straightforward report, no complexity

Straightforward report, no complexity

Tests for Better Outcomes

Early detection improves clinical decision-making by enabling timely interventions, leading to better maternal and neonatal outcomes, and raising the standard in maternal health.